For trial enrolment, see ClinicalTrials.gov
Tirzepatide raises resting heart rate by around 1.8 beats per minute on average, but the SURMOUNT trial programme didnt show an increase in arrhythmias or major adverse cardiac events compared to placebo
[2] Any patient presenting with suspected semaglutide overdose should undergo clinical assessment including vital signs, hydration status, blood glucose monitoring, and consideration of serum electrolytes and renal function
Some individuals report positive outcomes, such as increased energy, improved mood, and weight loss support
We offer injectable options including semaglutide (Ozempic/Wegovy), tirzepatide (Mounjaro/Zepbound) and retatrutide, as well as oral options including oral semaglutide (Rybelsus) and orforglipron (Foundayo)